KR20230038644A - 코로나바이러스 치료를 위한 피르페니돈 - Google Patents

코로나바이러스 치료를 위한 피르페니돈 Download PDF

Info

Publication number
KR20230038644A
KR20230038644A KR1020227039706A KR20227039706A KR20230038644A KR 20230038644 A KR20230038644 A KR 20230038644A KR 1020227039706 A KR1020227039706 A KR 1020227039706A KR 20227039706 A KR20227039706 A KR 20227039706A KR 20230038644 A KR20230038644 A KR 20230038644A
Authority
KR
South Korea
Prior art keywords
pirfenidone
release
subject
cov
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020227039706A
Other languages
English (en)
Korean (ko)
Inventor
에스투아르도 아귈라-코르도바
라우라 아귈라
호세 아구스틴 로헬리오 마가냐 카스트로
Original Assignee
엑스칼리버 파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑스칼리버 파마슈티컬즈, 인크. filed Critical 엑스칼리버 파마슈티컬즈, 인크.
Publication of KR20230038644A publication Critical patent/KR20230038644A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Biophysics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Inorganic Chemistry (AREA)
KR1020227039706A 2020-04-14 2021-04-14 코로나바이러스 치료를 위한 피르페니돈 Pending KR20230038644A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063010009P 2020-04-14 2020-04-14
US63/010,009 2020-04-14
PCT/US2021/027335 WO2021211745A1 (en) 2020-04-14 2021-04-14 Pirfenidone for coronavirus treatment

Publications (1)

Publication Number Publication Date
KR20230038644A true KR20230038644A (ko) 2023-03-21

Family

ID=78084909

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020227039706A Pending KR20230038644A (ko) 2020-04-14 2021-04-14 코로나바이러스 치료를 위한 피르페니돈

Country Status (14)

Country Link
US (1) US20230117397A1 (cg-RX-API-DMAC7.html)
EP (1) EP4135671A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023521887A (cg-RX-API-DMAC7.html)
KR (1) KR20230038644A (cg-RX-API-DMAC7.html)
CN (1) CN115916162A (cg-RX-API-DMAC7.html)
AU (1) AU2021254765A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022020821A2 (cg-RX-API-DMAC7.html)
CA (1) CA3175526A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002843A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022016155A2 (cg-RX-API-DMAC7.html)
EC (1) ECSP22087664A (cg-RX-API-DMAC7.html)
IL (1) IL297296A (cg-RX-API-DMAC7.html)
MX (1) MX2022012986A (cg-RX-API-DMAC7.html)
WO (1) WO2021211745A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2007009796A (es) 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
MX368750B (es) 2018-08-31 2019-10-15 Cell Therapy And Tech S A De C V Composiciones farmaceuticas semisolidas de base oleosa conteniendo pirfenidona para su aplicacion en la reparacion tisular.
CN114796122B (zh) * 2022-03-30 2023-03-24 山东大学 一种聚多巴胺载吡菲尼酮纳米粒及其制备方法和应用
JP7845721B2 (ja) * 2022-04-29 2026-04-14 オーバーシーズ ファーマシューティカルズ リミテッド ピルフェニドンの経口用持続放出性固形製剤

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU709178B2 (en) * 1995-09-19 1999-08-26 Intermune, Inc. Inhibition of tumor necrosis factor alpha
US20020028784A1 (en) * 2000-03-10 2002-03-07 Nest Gary Van Methods of preventing and treating viral infections using immunomodulatory polynucleotide sequences
US20030103941A1 (en) * 2001-10-09 2003-06-05 Crombleholme Timothy M. Materials and methods for preventing or reducing scar formation
WO2005013917A2 (en) * 2003-02-28 2005-02-17 Intermune, Inc. Combination therapy for treating alphavirus infection and liver fibrosis
WO2005000227A2 (en) * 2003-06-06 2005-01-06 Intermune, Inc. Methods of treating tnf-mediated disorders
WO2005040758A2 (en) * 2003-10-24 2005-05-06 Intermune, Inc. Use of pirfenidone in therapeutic regimens
AP2007004244A0 (en) * 2005-05-10 2007-12-31 Intermune Inc Method of modulating stress-activated protein kinase system
NZ591443A (en) * 2005-09-22 2013-04-26 Intermune Inc Granule formation of pirfenidone and pharmaceutically acceptable excipients
CN101088557A (zh) * 2006-06-12 2007-12-19 天津市扶素生物技术有限公司 用于预防或治疗hiv感染的药用组合物及其应用
US20080287508A1 (en) * 2007-05-18 2008-11-20 Intermune, Inc. Altering pharmacokinetics of pirfenidone therapy
WO2010132864A1 (en) * 2009-05-15 2010-11-18 Intermune, Inc. Methods of treating hiv patients with anti-fibrotics
CN101972236A (zh) * 2010-10-13 2011-02-16 北京诚创康韵医药科技有限公司 一种含吡非尼酮的缓释制剂
HUE058753T2 (hu) * 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
MX2011007675A (es) * 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
WO2013181691A1 (en) * 2012-06-04 2013-12-12 The Macfarlane Burnet Institute For Medical Research And Public Health Ltd A method of treatment and compositions useful therefor, screening and prognostic agents and uses therefor
JP7066321B2 (ja) * 2014-01-10 2022-05-13 アヴァリン ファーマ インク. エアロゾルのピルフェニドン及びピリドンのアナログの化合物、及び、その使用

Also Published As

Publication number Publication date
CL2022002843A1 (es) 2023-09-01
CN115916162A (zh) 2023-04-04
MX2022012986A (es) 2023-03-21
EP4135671A1 (en) 2023-02-22
ECSP22087664A (es) 2022-12-30
BR112022020821A2 (pt) 2022-12-20
IL297296A (en) 2022-12-01
EP4135671A4 (en) 2024-08-14
US20230117397A1 (en) 2023-04-20
WO2021211745A1 (en) 2021-10-21
CA3175526A1 (en) 2021-10-21
AU2021254765A1 (en) 2022-12-08
CO2022016155A2 (es) 2022-12-20
JP2023521887A (ja) 2023-05-25

Similar Documents

Publication Publication Date Title
US20230117397A1 (en) Pirfenidone for coronavirus treatment
US20200323843A1 (en) Use of levocetirizine and montelukast in the treatment of viral infection caused by coronavirus
AU2019328903B2 (en) Composition for eradicating Helicobacter pylori
CN105263579A (zh) 左西替利嗪和孟鲁司特在治疗血管炎中的用途
CN105163806A (zh) 左西替利嗪和孟鲁司特在治疗过敏反应中的用途
JP2019524767A (ja) 9−アミノメチルミノサイクリン化合物及びその使用
US20230111504A1 (en) Coronaviridae infection and avermectins
JP2010083871A (ja) 抗アデノウイルス剤を含有する医薬組成物
JP5232520B2 (ja) ロキソプロフェンを含有する抗アデノウイルス剤
JP4829478B2 (ja) 医薬組成物
CN119970700B (zh) Lmk235在制备用于治疗慢性尿路感染药物中的应用
US20230181582A1 (en) Compositions and methods for treating lung injuries associated with viral infections
CN121941502A (zh) 包含硫肽化合物的用于预防、减轻或治疗非结核分枝杆菌感染的组合物
CN103142614B (zh) 一种组合物产品的制药应用
TW202143985A (zh) 治療之方法
HK1199815B (en) Levocetirizine and montelukast for the treatment of influenza and common cold
CN102552257A (zh) 一种含有盐酸雷尼替丁和曲昔派特的复方制剂及其用途

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

PE0801 Dismissal of amendment

St.27 status event code: A-2-2-P10-P12-nap-PE0801

D12-X000 Request for substantive examination rejected

St.27 status event code: A-1-2-D10-D12-exm-X000

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902